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Background
There is a need for biomarkers to predict efficacy of adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC). Presented is a combined cisplatin and vinorelbine marker from a previously validated model system [1] tested in two cohorts.
Methods
The profiles consist of correlated in vitro cytotoxicity of cisplatin and vinorelbine and mRNA expressions. Then each profile is correlated to mRNA expression of 3500 tumors. The cohorts are 1) a publically available dataset with 133 completely resected stage Ib-II NSCLC patients, 71 of whom received adjuvant cisplatin and vinorelbine (ACT) and 62 patients who had no adjuvant treatment (OBS) [2] and 2) 95 stage Ib-IIIb completely resected NSCLC patients who all received adjuvant cisplatin and vinorelbine [3] .
Endpoint is cancer specific survival.
Results
The combined cisplatin and vinorelbine profiles scored as a continuous covariate showed 1) a Hazard Ratio ( A pooled analysis of the two treated cohorts resulted in a significant prediction (HR=0.187, (95% CI:0.069-0.508), p=0.001) up to 3 years from surgery using a random effects model.
Conclusions
The combined profiles demonstrate that NSCLC patients who benefit from cisplatin and vinorelbine can be identified. The profiles did not discriminate patients in the untreated arm. This holds promise for a predictive effect of the profiles and it is currently being validated in a prospective study [4] .
[1] PLoS ONE 2016, 11(2): e0148070.
[2] Zhu et al JCO 2010; 28:4417-4424 
Background
Multiple Myeloma is the next most common hematological malignancy and represents a continuous medical challenge since all patients eventually progress despite of many new drugs approved lately. The incidence of Multiple Myeloma is about 6 to 8 out of 100.000 in Western Countries. APO010 (a hexameric FAS-ligand) is an immune-oncology drug, which mimics cytotoxic T-lymphocyte signaling to induce apoptosis and could therefore be a new effective drug for Multiple Myeloma as these cells express CD95 (FAS-receptor).
Methods
Using a previously validated method by Medical Prognosis Institute A/S (MPI), we have developed an APO010 response predictor (APO010-DRP TM ), which is based on gene expression cluster obtained by comparing associations between gene expression profiles and growth inhibition by APO010 in a panel of cell lines. A second step has included filtering the identified gene expression profile against mRNA expression from a collection of 3200 human tumors, thereby making a predictive profile for APO010 responsiveness. We have initiated to screen relapsed/refractory Multiple Myeloma patients by isolating CD138 positive myeloma cells from the bone marrow and perform APO010-DRP TM in order to select the patients with the highest likelihood of benefit from APO010 treatment.
Results
Using the APO010-DRP TM analysis demonstrated Multiple Myeloma to be sensitive to APO010 compared to most solid tumors except breast cancer, which also appeared to be sensitive. First results from Multiple Myeloma patient screening will be presented at ESMO 2016.
Conclusion
Combining APO010 with DRP TM analysis will add a precision medicine element to immune-oncology treatment of Multiple Myeloma. This will enable us to identify patients with high likelihood of response and thereby facilitate focused future trial design and patient recruitment to achieve clinical success.
Om screeningverktyget Drug Response Predictor, DRP™
Oncology Venture använder screeningverktyget Drug Response Predictor, DRP™, från Medical Prognosis Institute för att välja ut de patienter som, utifrån den genetiska signaturen i sina tumörer, har högst sannolikhet att svara positivt på ett visst läkemedel. Målet är att utveckla rätt medicin för rätt patient och genom att screena patienterna innan behandling kan responsnivån signifikant höjas. DRP™-metoden bygger på jämförelser mellan känsliga och resistenta mänskliga cancercellinjer, med genetisk information från cellinjer, i kombination med klinisk tumörbiologi och kliniska korrelater i ett systemiskt biologiskt nätverk. DRP™ är baserad på budbärar-RNA från patienters biopsier. 
